Clinical trial · Observational
Effectiveness of Stereotactic RadioTherapy in Solid Primary Inoperable and Oligometastatic Cancer
Study of Effectiveness of Stereotactic Body RadioTherapy and Stereotactic RadioSurgery in Solid Primary Inoperable and Oligometastatic Cancer
NCT03461822CI-TRIAL-00032027ESRTSPIOCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to development of more effective treatment tactics of the stereotactic radiotherapy and radiosurgery alone and together with classic radiation therapy in primary inoperabel solid tumors and oligometastastatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- SRT in primary-inoperable solid tumors
- description
- stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in primary-inoperable solid tumors
- label
- Classic radiotherapy in primary-inoperable solid tumors
- description
- Classic radiotherapy in 1.8-2.0 Gy per fraction in primary-inoperable solid tumors
- label
- SRT in oligometastatic cancer
- description
- stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in oligometastatic cancer
- label
- Classic radiotherapy in oligometastatic cancer
- description
- Classic radiotherapy in 1.8-2.0 Gy per fraction in oligometastatic cancer
Primary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed primary-inoperable solid tumors or oligometastatic cancer. * Acceptance of patient by surgeon as non-operabel or refusing of surgery. * No more than 4 metastatic foci in irradiated organ. * Karnofsky scale more than 60. * Age ≥18 years. * Estimated duration of life \>3 months. * Hemoglobin ≥ 8 g/dl. * Absolute neutrophil count at least 1,500/mm\^3. * Platelet count at least 70,000/mm\^3. * Bilirubin no greater than 1.5 times normal. * SGOT and SGPT no greater than 3 times normal. * Creatinine less than 1.5 mg/dL. PT-INR/APTT less than 1.5. * Last patients data no older than 1 month. * No prior radiotherapy of same location. * Prior chemottherapy more than 2 weeks ago. Exclusion Criteria: * Progression of primary site of metastatic cancer. * Pregnancy or Breast-Feeding. * Decompensated concomitant diseases.
References
Publications (0)
Data not yet available
No reference posted for this study.